Moderna earnings date
Moderna (0QF) Q3 2026 Earnings Report
DE:0QF Q3 2026 EPS Results
- Actual EPS
- EUR 0.34
- Consensus EPS
- -EUR 0.99
- Beat/Miss
- Beat by +EUR 1.34
- One Year Ago EPS
- -EUR 0.46
DE:0QF Q3 2026 Revenue Results
- Actual Revenue
- EUR 1.19B
- Expected Revenue
- EUR 807.59M
- Beat/Miss
- Beat by +EUR 383.50M
- YoY Revenue Growth
- +29.23%
Earnings Announcement Details
- Quarter
- Q3 2026
- Date
- 11/06/2026
- Time
- Before Open
- Conference Call
- Friday, November 6, 2026
Moderna's next earnings date is estimated for February 25, 2027, based on past reporting schedules.
Q3 2026 Earnings Call Audio
Q3 2026 Earnings Slide Deck
Q3 2026 Earnings Call Summary
The call was strongly positive, driven by 29% third-quarter revenue growth, a raised full-year revenue outlook of 15% to 25% growth, improved cash and cost frameworks, expanded respiratory-vaccine approvals, and landmark Phase 3 melanoma efficacy results. The main negative developments were the 54% increase in cost of sales, the $900 million litigation charge, the norovirus program missing early-success criteria, slightly lower U.S. COVID vaccination trends, and remaining regulatory and development uncertainty in several programs. Highlights significantly outweighed lowlights.
For 2026, Moderna increased its full year revenue framework to a range of 15% to 25% growth, exceeding its prior framework of up to 10% growth, and expects an approximately even split between US and international revenue. Cost of sales is unchanged at $1.7 billion, including $900 million of expense related to the previously announced litigation settlement charge; R&D expense is $2.7 billion, SG&A expenses are approximately $1 billion, total GAAP operating expenses excluding the $900 million litigation charge are $4.5 billion, and cash costs are $3.8 billion. Taxes are expected to be negligible, capital expenditures are estimated at $200 million, and cash and investments are projected to be between $8.1 billion and $8.3 billion at the end of 2026; excluding the $2.6 billion net proceedss from the convertible note and cap call transaction, cash is projected to be $5.5 billion to $5.7 billion, with no additional drawdown from the remaining $900 million undrawn credit facility assumed.
- Strong Third-Quarter Revenue Growth and ProfitabilityManagement described a strong third quarter, with the CEO citing $1.4 billion in revenue, representing 29% year-over-year growth, and $200 million in net income. The CFO reported total revenue of $1.3 billion, also up 29% year over year, $162 million in net income, and diluted earnings per share of $0.38 versus a loss per share of $0.51 last year.
- Raised Full-Year 2026 Revenue OutlookThe company increased its full-year 2026 revenue framework to 15% to 25% growth from its prior framework of up to 10% growth. Management attributed the stronger outlook to increased demand, operational execution, shipment timing, MNEXSPIKE uptake, and strategic partnerships in the U.K., Canada, and Australia.
- Strong International Commercial PerformanceInternational revenue was $900 million year to date, already $200 million ahead of the full-year 2025 amount. Third-quarter revenue was approximately 60% U.S. and 40% international, and management said both regions delivered stronger-than-expected performance.
- Improved Cash Position and Financial DisciplineCash and investments ended the quarter at $8 billion, up from $6.9 billion at the end of the second quarter. The company reduced cash costs by 10% compared with the third quarter of last year and raised its projected year-end 2026 cash and investments range to $8.1 billion to $8.3 billion.
- Convertible Financing Strengthened the Balance SheetModerna raised $3 billion through a 0% convertible note and received approximately $2.6 billion in net proceeds after capped-call and transaction costs. Management said the financing provides long-term capital on attractive terms and strengthens the company's ability to invest in oncology.
- Lowered 2026 Expense and Capital Expenditure FrameworkThe company lowered its 2026 R&D expense outlook by $200 million to $2.7 billion and reduced its capital expenditure estimate to $200 million from a previous range of $200 million to $300 million. Excluding the $900 million litigation charge, projected total GAAP operating expenses are $4.5 billion and cash costs are $3.8 billion, each $200 million better than the previous framework.
- Expanded Approved Respiratory Vaccine PortfolioFDA approval of mFLUSIVA made it Moderna's fifth approved product and the first mRNA-based influenza vaccine to reach the market. Moderna also secured Canadian approvals for mFLUSIVA and mCOMBRIAX, while mNEXSPIKE received updated-strain approvals for the 2027 vaccination season in the United States, Canada, Japan, and Taiwan.
- Global Commercial Execution and Portfolio ExpansionmRESVIA is approved in 44 countries, and Moderna signed a five-year agreement with a local manufacturer in Mexico to support COVID-19 vaccine supply. mCOMBRIAX has approvals in Europe and Canada, while mFLUSIVA has approvals in the United States and Canada with reviews ongoing in the European Union, Australia, and Taiwan.
- Healthy U.S. Respiratory Vaccination DemandThrough late October, approximately 44.1 million flu, COVID-19, and RSV vaccinations had been administered in U.S. retail and long-term-care channels, a 3% increase over the comparable period last year. Management said flu vaccinations were slightly ahead of last year and overall seasonal respiratory vaccine demand remained strong.
- Positive mRESVIA Revaccination ResultsA Phase 3 revaccination study of mRESVIA in adults aged 60 and older who had previously received a protein-based RSV vaccine demonstrated robust immune responses comparable to those following initial mRESVIA vaccination, with no new safety concerns identified.
- Landmark Phase 3 Melanoma Results for IntismeranIn the INTerpath-001 trial, intismeran plus pembrolizumab produced a 42% reduction in the risk of recurrence or death versus pembrolizumab alone, with a hazard ratio of 0.58 and a p-value below 0.001. At two years, recurrence-free survival was 82.2% for the combination versus 70% for pembrolizumab alone, a 12 percentage point absolute improvement. The company characterized the result as the first positive Phase 3 trial for an individualized cancer vaccine and the first positive Phase 3 trial demonstrating benefit over anti-PD-1 therapy in adjuvant melanoma.
- Additional Intismeran Sensitivity Analysis Showed Greater BenefitA prespecified modified intent-to-treat analysis showed a 49% reduction in the risk of recurrence or death, with a hazard ratio of 0.51. Two-year recurrence-free survival was 84.2% with the combination versus 70.4% with pembrolizumab alone, representing nearly a 14 percentage point absolute improvement.
- Favorable Intismeran Safety ProfileThe combination of intismeran and pembrolizumab was generally well tolerated, with findings consistent with the known safety profiles of the individual therapies. Pembrolizumab-associated adverse events of interest occurred in 36% of combination patients versus 35% of pembrolizumab-alone patients; the most common combination-arm adverse events were pyrexia, injection-site pain, and fatigue, generally described as low grade and transient.
- Broad Advancement of the Oncology PipelineThe intismeran program is advancing across multiple tumor types. The adjuvant Phase 3 non-small-cell lung cancer study is fully enrolled, two additional Phase 3 lung cancer studies continue to enroll, Phase 2 renal cell carcinoma and muscle-invasive bladder cancer studies are fully enrolled, and Phase 1 pancreatic and gastric cancer studies are fully enrolled. Moderna also continues Phase 2 studies in bladder cancer, metastatic melanoma, and squamous and non-small-cell lung cancer.
- Encouraging Pancreatic Cancer Immunogenicity DataIn a Phase 1 pancreatic cancer study, Moderna generated neoantigen-specific T-cell responses in all 19 evaluable patients despite the low tumor mutational burden typically seen in pancreatic cancer. The therapy was administered with FOLFIRINOX, and management said the data supported its ability to generate T-cell reactivity in the presence of chemotherapy.
- Progress Across Additional Oncology ModalitiesThe company is advancing cancer antigen therapies, T-cell engagers, and cell-therapy enhancement programs. The mRNA-2.81 thousand multiple myeloma program was selected for an oral presentation at the upcoming ASH meeting, with a later data cut expected to include more patients, longer follow-up, and evaluation of deeper responses and activity in patients previously treated with BCMA and GPRC5D therapies.
- Global Health and Rare-Disease Pipeline ProgressModerna's Ebola vaccine candidate mRNA-1.47 thousand, developed with SAPI, was selected to advance into Phase 2/3 following a recommendation from the WHO technical advisory group. The registrational propionic acidemia trial remains on track, with results expected later this year.
- Key Near-Term Clinical and Regulatory MilestonesManagement identified upcoming milestones including the event-driven Phase 2 renal-cell-carcinoma readout, the intismeran BLA submission, presentation of mRNA-2.81 thousand data at ASH, and the registrational propionic acidemia readout. The company is working with Merck to submit the intismeran BLA this year and said that, if the process proceeds as expected, approval could occur next year.
DE:0QF Earnings History
| Report Date | Fiscal Quarter | Forecast / EPS | Last Year's EPS | EPS YoY Change | Press Release |
|---|---|---|---|---|---|
| Feb 25, 2027 | 2026 (Q4) | -1.89- | -1.91 | ― | ― |
| Nov 06, 2026 | 2026 (Q3) | -0.990.34 | -0.46 | 174.51% (+0.81) | |
| Jul 31, 2026 | 2026 (Q2) | -1.84-1.79 | -1.93 | 7.51% (+0.15) | |
| May 01, 2026 | 2026 (Q1) | -4.03-3.08 | -2.29 | -34.92% (-0.80) | |
| Feb 13, 2026 | 2025 (Q4) | -2.31-1.91 | -2.64 | 27.49% (+0.73) | |
| Nov 06, 2025 | 2025 (Q3) | -1.70-0.46 | 0.03 | -1800.00% (-0.49) | |
| Aug 01, 2025 | 2025 (Q2) | -2.71-1.93 | -3.02 | 36.04% (+1.09) | |
| May 01, 2025 | 2025 (Q1) | -2.83-2.29 | -2.78 | 17.92% (+0.50) | |
| Feb 14, 2025 | 2024 (Q4) | -2.43-2.64 | 0.5 | -629.09% (-3.14) | |
| Nov 07, 2024 | 2024 (Q3) | ―0.03 | -8.65 | 100.31% (+8.67) |
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.


